股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 潤邁德醫療有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02297 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,800,000,000 | HKD | | 0.0001 | HKD | | 380,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,800,000,000 | HKD | | 0.0001 | HKD | | 380,000 | 本月底法定/註冊股本總額 ...

| 目錄 | | --- | | 2 | 公司資料 | | --- | --- | | 4 | 財務摘要 | | 11 | 管理層討論與分析 | | 17 | 企業管治及其他資料 | | 29 | 中期簡明綜合損益表 | | 30 | 中期簡明綜合損益及其他全面收益表 | | 31 | 中期簡明綜合財務狀況表 | | 33 | 中期簡明綜合權益變動表 | | 34 | 中期簡明綜合現金流量表 | | 35 | 中期簡明綜合財務資料附註 | | 57 | 釋義 | 中期報告2025 1 公司資料 董事會 執行董事 霍雲飛先生 （主席） 朱則柯先生 （聯席首席執行官） （於2025年7月15日獲委任） 段靜女士（於2025年7月15日獲委任） 呂永輝先生（於2025年7月15日辭任） 谷陽女士 （副總裁） （於2025年7月15日辭任） 非執行董事 王霖先生 衡磊先生 霍雲龍博士 獨立非執行董事 廖船江先生 陳雪峰先生 趙暉先生（於2025年7月15日獲委任） 李浩民先生（於2025年6月13日辭任） 審核委員會 廖船江先生 （主席） 陳雪峰先生 趙暉先生（於2025年7月15日獲委任） 李浩民先生（於2025年 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示，概不就因本公告的全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Rainmed Medical Limited 潤邁德醫療有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2297） 有關截至二零二五年六月三十日止六個月 中期業績公告之澄清公告 除上文所述外，二零二五年中期業績公告之所有其他資料維持不變。 承董事會命 潤邁德醫療有限公司 董事會主席兼執行董事 霍雲飛 香港，二零二五年九月二十八日 於本公告日期，董事會由執行董事霍雲飛先生、朱則柯先生及段靜女士；非執行董事霍雲龍博士、王霖先生及衡磊先生； 及獨立非執行董事廖船江先生、陳雪峰先生及趙暉先生組成。 茲提述潤邁德醫療有限公司（「本公司」）日期為二零二五年八月二十八日有關截至二零二五 年六月三十日止六個月之中期業績公告（「二零二五年中期業績公告」）。本公司謹此澄清， 二零二五年中期業績公告所披露之「已發行普通股加權平均數」及「每股基本及攤薄虧損」 存在無意之錯誤。本公司謹此澄清，本公司截至二零二五年六月 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 潤邁德醫療有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02297 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,800,000,000 | HKD | | 0.0001 | HKD | | 380,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,800,000,000 | HKD | | 0.0001 | HKD | | 380,000 | 本月底法定/註冊股本總額： ...

润迈德-B(02297)发布截至2025年6月30日止六个月业绩，该集团期内取得收入1040万元，同比减少 61.3%;公司股东应占亏损3220万元，同比收窄22.6%;每股基本亏损0.02元。 ...

Group 1 - The company reported a revenue of 10.4 million, representing a year-on-year decrease of 61.3% [1] - The loss attributable to shareholders was 32.2 million, which narrowed by 22.6% year-on-year [1] - The basic loss per share was 0.02 yuan [1]

[Report Cover and Basic Information](index=1&type=section&id=%E6%8A%A5%E5%91%8A%E5%B0%81%E9%9D%A2%E4%B8%8E%E5%9F%BA%E6%9C%AC%E4%BF%A1%E6%81%AF) [Financial Highlights](index=1&type=section&id=%E8%B4%A2%E5%8A%A1%E6%91%98%E8%A6%81) The company's unaudited interim financial performance for the six months ended June 30, 2025, shows significant declines in revenue and gross profit, a narrowed loss attributable to shareholders, and no interim dividend declaration | Indicator | 2025 (RMB million) | 2024 (RMB million) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 10.4 | 26.9 | -61.3% | | Gross Profit | 5.1 | 18.7 | -72.7% | | Gross Profit Margin | 49.0% | 69.5% | -20.5% | | Loss Attributable to Company Shareholders | (32.2) | (41.6) | -22.6% | | Adjusted Non-HKFRS Loss Attributable to Company Shareholders | (33.8) | (40.2) | -15.9% | | Basic and Diluted Loss Per Share (RMB) | (0.02) | (0.04) | -50.0% | - The Board resolved not to declare any interim dividend for the six months ended June 30, 2025[2](index=2&type=chunk) - The Group incurred a loss of **RMB 33.3 million**, primarily due to ongoing expenses for R&D, manufacturing, and commercialization of medical devices[2](index=2&type=chunk) [Unaudited Interim Condensed Consolidated Financial Statements](index=2&type=section&id=%E6%9C%AA%E7%BB%8F%E5%AE%A1%E6%A0%B8%E4%B8%AD%E6%9C%9F%E7%AE%80%E6%98%8E%E7%BB%BC%E5%90%88%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) [Unaudited Interim Condensed Consolidated Statement of Profit or Loss](index=2&type=section&id=%E6%9C%AA%E7%BB%8F%E5%AE%A1%E6%A0%B8%E4%B8%AD%E6%9C%9F%E7%AE%80%E6%98%8E%E7%BB%BC%E5%90%88%E6%94%B6%E7%9B%8A%E8%A1%A8) This statement presents the unaudited interim condensed consolidated statement of profit or loss for the six months ended June 30, 2025, showing significant declines in revenue and gross profit, but narrowed operating and period losses | Indicator | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | Revenue | 10,405 | 26,868 | | Cost of Sales | (5,288) | (8,215) | | Gross Profit | 5,117 | 18,653 | | Research and Development Expenses | (6,362) | (18,469) | | Selling Expenses | (15,090) | (29,607) | | General and Administrative Expenses | (20,644) | (23,356) | | Operating Loss | (33,238) | (44,666) | | Loss for the Period | (33,291) | (42,728) | | Loss Attributable to Company Shareholders | (32,169) | (41,646) | - Loss for the period narrowed year-on-year from **RMB 42,728 thousand** in 2024 to **RMB 33,291 thousand** in 2025[3](index=3&type=chunk) [Unaudited Interim Condensed Consolidated Statement of Comprehensive Income](index=3&type=section&id=%E6%9C%AA%E7%BB%8F%E5%AE%A1%E6%A0%B8%E4%B8%AD%E6%9C%9F%E7%AE%80%E6%98%8E%E7%BB%BC%E5%90%88%E5%85%A8%E9%9D%A2%E6%94%B6%E7%9B%8A%E8%A1%A8) This statement presents the unaudited interim condensed consolidated statement of comprehensive income for the six months ended June 30, 2025, indicating a year-on-year decrease in total comprehensive expense, primarily due to exchange differences | Indicator | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | Loss for the Period | (33,291) | (42,728) | | Exchange Differences Arising from Translation of the Company | (6,407) | 2,910 | | Exchange Differences Arising from Translation of Subsidiaries | 3,818 | (1,303) | | Other Comprehensive (Expense) Income for the Period, Net of Tax | (2,589) | 1,607 | | Total Comprehensive Expense for the Period | (35,880) | (41,121) | - Exchange differences arising from translation of the Company changed from an income of **RMB 2,910 thousand** in 2024 to an expense of **RMB 6,407 thousand** in 2025[4](index=4&type=chunk) [Unaudited Interim Condensed Consolidated Statement of Financial Position](index=4&type=section&id=%E6%9C%AA%E7%BB%8F%E5%AE%A1%E6%A0%B8%E4%B8%AD%E6%9C%9F%E7%AE%80%E6%98%8E%E7%BB%BC%E5%90%88%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) This statement provides the unaudited interim condensed consolidated statement of financial position as of June 30, 2025, showing increases in total assets and liabilities, a slight decrease in equity attributable to company shareholders, and a reduction in net current assets | Indicator | 2025 June 30 (RMB thousand) | 2024 December 31 (RMB thousand) | | :--- | :--- | :--- | | Total Assets | 504,248 | 463,060 | | Total Liabilities | 96,955 | 53,148 | | Total Equity | 407,293 | 409,912 | | Equity Attributable to Company Shareholders | 405,498 | 406,995 | | Net Current Assets | 144,545 | 189,574 | - Current liabilities significantly increased from **RMB 48,338 thousand** as of December 31, 2024, to **RMB 96,592 thousand** as of June 30, 2025, primarily due to increases in trade and other payables and borrowings[6](index=6&type=chunk) - Net current assets decreased from **RMB 189.6 million** as of December 31, 2024, to **RMB 144.5 million** as of June 30, 2025, mainly attributable to a decrease in bank deposits maturing in over three months[6](index=6&type=chunk) [Notes to the Unaudited Interim Condensed Consolidated Financial Information](index=6&type=section&id=%E6%9C%AA%E7%BB%8F%E5%AE%A1%E6%A0%B8%E4%B8%AD%E6%9C%9F%E7%AE%80%E6%98%8E%E7%BB%BC%E5%90%88%E8%B4%A2%E5%8A%A1%E8%B5%84%E6%96%99%E9%99%84%E6%B3%A8) [General Information](index=6&type=section&id=%E4%B8%80%E8%88%AC%E8%B5%84%E6%96%99) This chapter outlines the company's registration details, principal place of business, and core operations, focusing on the R&D, manufacturing, and commercialization of medical devices related to caFFR, caIMR systems, and IVD products - The Company was incorporated as a limited company in the Cayman Islands on April 9, 2021, with its shares listed on the Main Board of the Stock Exchange on July 8, 2022[7](index=7&type=chunk)[8](index=8&type=chunk) - The Company and its subsidiaries are primarily engaged in the R&D, manufacturing, and commercialization of medical devices related to caFFR systems, caIMR systems, and IVD products in China, Europe, and other regions[7](index=7&type=chunk) [Basis of Preparation and Accounting Policies](index=6&type=section&id=%E7%BC%96%E5%88%B6%E5%9F%BA%E5%87%86%E4%B8%8E%E4%BC%9A%E8%AE%A1%E6%94%BF%E7%AD%96) This chapter details that the interim financial information is prepared in accordance with HKAS 34 issued by the HKICPA, noting no significant impact from new amendments applied during the period - The interim financial information has been prepared in accordance with Hong Kong Accounting Standard 34 'Interim Financial Reporting' issued by the Hong Kong Institute of Certified Public Accountants[10](index=10&type=chunk) - The application of amendments to Hong Kong Financial Reporting Standards during this interim period had no significant impact on the Group's financial performance and position[11](index=11&type=chunk) [Segment and Revenue Information](index=7&type=section&id=%E5%88%86%E9%83%A8%E5%8F%8A%E6%94%B6%E7%9B%8A%E8%B5%84%E6%96%99) This chapter details the company's revenue composition, contract liabilities, geographical distribution, and key customer information, indicating product sales as the primary revenue source and China as the main contributor - The Group has only one reportable operating segment, which is the R&D, manufacturing, and commercialization of medical devices related to caFFR systems, caIMR systems, and IVD products[12](index=12&type=chunk) Revenue Recognition Timing | Revenue Recognition Timing | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | Product Sales | 9,774 | 26,560 | | Installation and Training Services | 631 | 308 | | **Total Revenue** | **10,405** | **26,868** | Revenue by Geographical Region | Region | 2025 Revenue (RMB thousand) | 2024 Revenue (RMB thousand) | | :--- | :--- | :--- | | China | 9,461 | 26,497 | | Other | 944 | 371 | | **Total** | **10,405** | **26,868** | - As of June 30, 2025, all of the Group's non-current assets are located in China[15](index=15&type=chunk) [Analysis of Expenses](index=9&type=section&id=%E5%BC%80%E6%94%AF%E5%88%86%E6%9E%90) This chapter details the composition of cost of sales, R&D expenses, selling expenses, and general and administrative expenses, highlighting employee benefit expenses and raw material costs as major components Expense Categories | Expense Category | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | Employee Benefit Expenses | 26,604 | 45,550 | | Professional Services | 1,406 | 2,391 | | Depreciation and Amortization Expenses | 10,619 | 11,481 | | Raw Material Costs | 2,768 | 7,526 | | Travel Expenses | 2,158 | 3,347 | | Promotion and Entertainment Expenses | 2,153 | 4,422 | | Clinical Trial and Testing Expenses | – | 1,892 | | **Total** | **47,384** | **79,647** | - Total expenses decreased from **RMB 79,647 thousand** in 2024 to **RMB 47,384 thousand** in 2025, a year-on-year decrease of approximately **40.5%**[17](index=17&type=chunk) [Income Tax Expense](index=9&type=section&id=%E6%89%80%E5%BE%97%E7%A8%85%E9%96%8B%E6%94%AF) This chapter details the Group's income tax expense and applicable tax rates, noting that Suzhou Rainmed, a PRC subsidiary, enjoys a 15% preferential tax rate as a high-tech enterprise, with no PRC income tax provision made for the period Income Tax Expense Summary | Indicator | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | Current Income Tax Expense | (9) | (302) | | Deferred Income Tax | – | 16 | | **Income Tax Expense** | **(9)** | **(286)** | - No provision for Hong Kong profits tax has been made for Hong Kong-registered subsidiaries as they had no estimated assessable profits[19](index=19&type=chunk) - Suzhou Rainmed was certified as a high-tech enterprise in December 2024, enjoying a **15%** preferential income tax rate from January 1, 2024, and eligible for a **200%** super deduction for R&D expenses[20](index=20&type=chunk)[21](index=21&type=chunk) [Loss Per Share](index=10&type=section&id=%E6%AF%8F%E8%82%A1%E8%99%A7%E6%90%8D) This chapter calculates basic and diluted loss per share for the six months ended June 30, 2025, showing a narrowed loss per share year-on-year, with diluted loss per share being the same as basic due to anti-dilutive potential ordinary shares Loss Per Share Calculation | Indicator | 2025 (Unaudited) | 2024 (Unaudited) | | :--- | :--- | :--- | | Loss Attributable to Company Shareholders (RMB thousand) | (32,169) | (41,646) | | Weighted Average Number of Ordinary Shares Issued (thousand shares) | 1,401,359 | 1,167,799 | | Basic Loss Per Share (RMB/share) | (0.02) | (0.04) | - Basic loss per share narrowed from **RMB (0.04)** in 2024 to **RMB (0.02)** in 2025[23](index=23&type=chunk) - Diluted loss per share for the six months ended June 30, 2025, and 2024, was the same as basic loss per share due to the anti-dilutive effect of potential ordinary shares[24](index=24&type=chunk) [Trade and Other Receivables](index=11&type=section&id=%E8%B4%B8%E6%98%93%E5%8F%8A%E5%85%B6%E4%BB%96%E5%BA%94%E6%94%B6%E6%AC%BE%E9%A1%B9) This chapter details the composition and aging analysis of trade and other receivables, showing increases in both net and gross trade receivables, with other receivables primarily comprising recoverable VAT and employee loans Trade and Other Receivables Summary | Indicator | 2025 June 30 (RMB thousand) | 2024 December 31 (RMB thousand) | | :--- | :--- | :--- | | Net Trade Receivables | 2,271 | 2,088 | | Net Other Receivables | 19,252 | 16,754 | | **Net Trade and Other Receivables** | **21,505** | **18,486** | Aging Analysis of Trade Receivables | Trade Receivables Aging | 2025 June 30 (RMB thousand) | 2024 December 31 (RMB thousand) | | :--- | :--- | :--- | | Within 30 Days | 977 | 359 | | 30 to 90 Days | 752 | 183 | | 91 to 180 Days | 195 | 411 | | 181 to 365 Days | 44 | 611 | | 1 to 2 Years | 395 | 709 | | **Total** | **2,363** | **2,273** | - Other receivables primarily include employee loans of **RMB 3,251 thousand**, deposits of **RMB 1,307 thousand**, and recoverable VAT of **RMB 13,323 thousand**[26](index=26&type=chunk) [Dividends](index=12&type=section&id=%E8%82%A1%E6%81%AF) This chapter confirms that neither the Company nor any of its group companies paid or declared any dividends for the six months ended June 30, 2025, and 2024 - Neither the Company nor any of its current group companies paid or declared any dividends for each of the six-month periods ended June 30, 2025, and 2024[28](index=28&type=chunk) [Trade and Other Payables](index=13&type=section&id=%E8%B4%B8%E6%98%93%E5%8F%8A%E5%85%B6%E4%BB%96%E5%BA%94%E4%BB%98%E6%AC%BE%E9%A1%B9) This chapter presents the composition and aging analysis of trade and other payables, indicating a significant increase in amounts payable for construction in progress, leading to a substantial rise in total payables Trade and Other Payables Summary | Indicator | 2025 June 30 (RMB thousand) | 2024 December 31 (RMB thousand) | | :--- | :--- | :--- | | Trade Payables | 600 | 559 | | Accrued Staff Salaries and Benefits | 4,775 | 5,675 | | Other Taxes Payable | 4,728 | 4,736 | | Amounts Payable for Construction in Progress | 45,266 | – | | Amounts Payable to Service Providers | – | 6,837 | | Other Accrued Expenses | 1,771 | 3,140 | | **Total** | **57,140** | **20,947** | - Amounts payable for construction in progress increased from zero as of December 31, 2024, to **RMB 45,266 thousand** as of June 30, 2025, being the primary reason for the significant growth in trade and other payables[29](index=29&type=chunk) [Business Review and Outlook](index=14&type=section&id=%E4%B8%9A%E5%8A%A1%E5%9B%9E%E9%A1%BE%E4%B8%8E%E5%B1%95%E6%9C%9B) [Company Overview](index=14&type=section&id=%E5%85%AC%E5%8F%B8%E6%A6%82%E8%A7%88) The company aims to be a global leader in vascular interventional surgical robotics, focusing on the design, development, and commercialization of caFFR, caIMR systems, and IVD products to improve coronary artery disease diagnosis and treatment through innovative medical devices - Core products, the caFFR and caIMR systems, are used to assess the severity of myocardial ischemia caused by coronary artery stenosis and microvascular dysfunction, aiming to replace pressure guidewires and enhance diagnostic efficiency and accuracy[30](index=30&type=chunk) - The caFFR system has received European CE certification, NMPA, and approvals from multiple other countries, while the caIMR system obtained NMPA approval in April 2023, making it the world's first commercially approved minimally invasive IMR system[31](index=31&type=chunk) - In March 2023, the Group acquired a **68.32%** equity interest in Tianjin Yuehekang Biotechnology Co., Ltd., expanding into biochemical in-vitro diagnostic reagents and enhancing its product portfolio[32](index=32&type=chunk) [Commercialization](index=15&type=section&id=%E5%95%86%E4%B8%9A%E5%8C%96) The company continues to expand market channels for caFFR, caIMR, and IVD systems, and despite a year-on-year revenue decrease, has established a broad domestic distribution network, actively pursuing international commercialization, with core products covering over 780 hospitals in China - As of June 30, 2025, the company has established a vast distribution network of **157** domestic distributors, covering over **320** hospitals across **21** provinces, four autonomous regions, and four municipalities in China[34](index=34&type=chunk) - As of June 30, 2025, the company has cumulatively sold and installed core products in over **780** hospitals, with over **1,480** hospitals in China having used its core products[34](index=34&type=chunk) - Proprietary consumables for the caFFR system have obtained self-pay prices for patients in **33** provinces and regions, with **24** of these included in medical insurance reimbursement lists[34](index=34&type=chunk) [Research and Development](index=16&type=section&id=%E7%A0%94%E5%8F%91) The company possesses a dedicated in-house R&D team focused on innovative products in interventional precision diagnosis and treatment, having established four R&D platforms, and as of June 30, 2025, holds **210** granted patents and **67** pending patent applications - The company has four major R&D platforms: medical imaging algorithm and application R&D platform, fluid dynamics simulation computing platform, high-performance device R&D platform, and interventional consumables R&D platform[35](index=35&type=chunk) - As of June 30, 2025, the company holds **210** granted patents (**183** in China, **7** in the US, **4** in Europe, **16** in Japan) and **67** pending patent applications[35](index=35&type=chunk) [Manufacturing](index=16&type=section&id=%E5%88%B6%E9%80%A0) The company operates three GMP-compliant production sites totaling approximately **7,962** square meters, with an estimated annual capacity of **11,375** consoles, **1,130,765** pressure sensors, and over **80** IVD products, and plans to build its own production and R&D base - As of June 30, 2025, the company has three production sites, two in Suzhou, Jiangsu Province, China, and one in Tianjin, China, totaling approximately **7,962** square meters, all compliant with China's GMP standards for medical devices[36](index=36&type=chunk) - The estimated annual production capacity is **11,375** consoles, **1,130,765** pressure sensors, and over **80** categories of IVD products[36](index=36&type=chunk) - In May 2023, the company acquired approximately **20,000** square meters of land to build its own production and R&D base, aiming to integrate existing facilities and enhance overall capabilities[36](index=36&type=chunk) [Products and Pipeline](index=17&type=section&id=%E4%BA%A7%E5%93%81%E5%8F%8A%E7%AE%A1%E7%BA%BF) This chapter details the R&D and commercialization progress of the company's core products: caFFR system, caIMR system, Flash Robot vascular interventional navigation surgical system, and IVD product lines, listing each product's indications, type, and stage Product Pipeline Overview | Product | Indication | Type | Stage | Approval/Launch | | :--- | :--- | :--- | :--- | :--- | | caFFR System | Coronary Artery Disease | III (China) | Post-market Clinical Trials | Launched (CE, NMPA, Korea) | | caIMR System | Coronary Artery Disease | III (China) | Post-market Clinical Trials | Launched (NMPA, Brazil, Korea) | | Flash Robot Vascular Interventional Navigation Surgical System | Coronary Artery Disease | III | Research Refinement Stage | － | | IVD Products | Biochemical In-vitro Diagnostic Reagents | Class II | 85 Registration Certificates Obtained | Launched | | FlashAngio caFFR System Sales | - | - | - | 66 (2025) vs 15 (2024) | | FlashPressure caFFR Pressure Sensor Sales | - | - | - | 6,781 (2025) vs 21,142 (2024) | | FlashAngio caIMR System Sales | - | - | - | 630 (2025) vs 1,731 (2024) | | IVD Product Sales | - | - | - | 2,297 (2025) vs 3,673 (2024) | - The caFFR system obtained European CE certification in September 2019 and NMPA registration in December 2019, with ongoing post-market clinical trials for indication expansion[40](index=40&type=chunk) - The caIMR system is the world's only minimally invasive IMR measurement product to complete confirmatory clinical trials, receiving NMPA approval for commercialization in April 2023[41](index=41&type=chunk) - The IVD product business has obtained **85** Class II registration certificates for biochemical diagnostic reagents and is developing innovative cardiovascular IVD precision diagnostic products such as 'coagulation' and 'copeptin'[43](index=43&type=chunk) [Outlook and Prospects](index=19&type=section&id=%E5%B1%95%E6%9C%9B%E5%8F%8A%E5%89%8D%E6%99%AF) Despite a challenging market in H1 2025, the company achieved certain results, with caIMR system commercialization approval and IVD market entry via Tianjin Yuehekang acquisition; H2 plans include strengthening FFR/IMR advantages, expanding IVD coverage, and pursuing overseas markets for positive full-year growth - The core product, caIMR system, successfully obtained commercialization approval from the NMPA and the Brazilian National Health Surveillance Agency[44](index=44&type=chunk) - The acquisition of Tianjin Yuehekang strategically positions the company in the in-vitro diagnostics field, further enhancing its product pipeline[44](index=44&type=chunk) - The company plans to strengthen its competitive advantages in FFR and IMR, expand IVD product coverage and market presence, actively pursue overseas markets, and enhance domestic market penetration in the second half of the year, aiming for positive full-year growth in 2025[44](index=44&type=chunk) [Management Discussion and Analysis of Financial Performance](index=20&type=section&id=%E8%B4%A2%E5%8A%A1%E8%A1%A8%E7%8E%B0%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) [Revenue](index=20&type=section&id=%E6%94%B6%E5%85%A5) This chapter analyzes the company's revenue for the six months ended June 30, 2025, showing a significant **61.3%** year-on-year decrease in total revenue, primarily due to reduced sales of FlashPressure caFFR pressure sensors and caIMR systems Revenue by Product Category | Product Category | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | FlashAngio caFFR System Sales | 66 | 15 | | FlashPressure caFFR Pressure Sensor Sales | 6,781 | 21,142 | | FlashAngio caIMR System Sales | 630 | 1,731 | | IVD Product Sales | 2,297 | 3,673 | | Installation and Training Services | 631 | 308 | | **Total** | **10,405** | **26,869** | - Total revenue decreased by approximately **61.3%** year-on-year, mainly due to reduced sales of FlashPressure caFFR pressure sensors and caIMR systems[45](index=45&type=chunk) [Gross Profit and Gross Profit Margin](index=20&type=section&id=%E6%AF%9B%E5%88%A9%E5%8F%8A%E6%AF%9B%E5%88%A9%E7%8E%87) This chapter analyzes the company's gross profit and gross profit margin, showing a **72.7%** year-on-year decrease in gross profit and a decline in gross profit margin to **49.0%**, primarily due to reduced caFFR system sales and depreciation and amortization expenses for new production facilities Gross Profit and Margin Summary | Indicator | 2025 (RMB million) | 2024 (RMB million) | Change (%) | | :--- | :--- | :--- | :--- | | Gross Profit | 5.1 | 18.7 | -72.7% | | Gross Profit Margin | 49.0% | 69.5% | -20.5% | - The decrease in gross profit margin was mainly due to depreciation and amortization expenses for newly utilized major production facilities[46](index=46&type=chunk) [Research and Development Expenses](index=21&type=section&id=%E7%A0%94%E7%99%BC%E9%96%8B%E6%94%AF) This chapter analyzes the company's R&D expenses, showing a year-on-year decrease of approximately **65.6%**, primarily due to reduced employee benefit expenses from cost control and decreased clinical trial and testing expenses due to fewer new R&D projects R&D Expense Categories | Expense Category | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | Employee Benefit Expenses | 4,635 | 9,034 | | Raw Material Costs | 356 | 4,674 | | Clinical Trial and Testing Expenses | – | 1,892 | | **Total** | **6,362** | **18,469** | - R&D expenses decreased by approximately **65.6%** year-on-year, mainly due to a **RMB 4.4 million** reduction in employee benefit expenses and a **RMB 1.9 million** reduction in clinical trial and testing expenses[48](index=48&type=chunk) [Selling Expenses](index=22&type=section&id=%E9%8A%B7%E5%94%AE%E9%96%8B%E6%94%AF) This chapter analyzes the company's selling expenses, showing a year-on-year decrease of approximately **49.0%**, primarily due to reduced employee benefit expenses from cost control and decreased marketing development expenses from fewer sales and marketing activities Selling Expense Categories | Expense Category | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | Employee Benefit Expenses | 9,713 | 20,204 | | Marketing Development Expenses | 5,126 | 7,817 | | **Total** | **15,090** | **29,607** | - Selling expenses decreased by approximately **49.0%** year-on-year, mainly due to a **RMB 10.5 million** reduction in employee benefit expenses and a **RMB 2.7 million** reduction in marketing development expenses[49](index=49&type=chunk) [General and Administrative Expenses](index=23&type=section&id=%E4%B8%80%E8%88%AC%E8%A1%8C%E6%94%BF%E9%96%8B%E6%94%AF) This chapter analyzes the company's general and administrative expenses, showing a year-on-year decrease of approximately **11.6%**, primarily due to reduced employee benefit expenses associated with a decrease in salaried and administrative staff General and Administrative Expense Categories | Expense Category | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | Employee Benefit Expenses | 10,754 | 12,801 | | Depreciation and Amortization Expenses | 6,086 | 5,372 | | Professional Service Expenses | 1,156 | 965 | | Other Expenses | 2,648 | 4,218 | | **Total** | **20,644** | **23,356** | - General and administrative expenses decreased by approximately **11.6%** year-on-year, mainly due to a **RMB 2.0 million** reduction in employee benefit expenses[51](index=51&type=chunk) [Other Income](index=23&type=section&id=%E5%85%B6%E4%BB%96%E6%94%B6%E5%85%A5) This chapter analyzes the company's other income, showing a significant year-on-year decrease, primarily due to a one-off government grant received in 2024 Other Income Summary | Indicator | 2025 (RMB million) | 2024 (RMB million) | | :--- | :--- | :--- | | Other Income | 1.0 | 7.3 | - The decrease in other income was mainly due to a one-off government grant received in 2024[52](index=52&type=chunk) [Income Tax Expense](index=24&type=section&id=%E6%89%80%E5%BE%97%E7%A8%8E%E9%96%8B%E6%94%AF) This chapter analyzes the company's income tax expense, showing a significant year-on-year decrease, primarily due to lower profit generated by a subsidiary from interest income Income Tax Expense Summary | Indicator | 2025 (RMB million) | 2024 (RMB million) | | :--- | :--- | :--- | | Income Tax Expense | 0.01 | 0.3 | - The decrease in income tax expense was mainly due to lower profit generated by a subsidiary from interest income[53](index=53&type=chunk) [Loss for the Period](index=24&type=section&id=%E6%9C%9F%E5%85%A7%E8%99%A7%E6%90%8D) This chapter summarizes the company's loss for the six months ended June 30, 2025, indicating a narrowed loss year-on-year Loss for the Period Summary | Indicator | 2025 (RMB million) | 2024 (RMB million) | | :--- | :--- | :--- | | Loss for the Period | 33.3 | 42.7 | - Loss for the period narrowed from **RMB 42.7 million** in 2024 to **RMB 33.3 million** in 2025[54](index=54&type=chunk) [Liquidity and Financial Resources](index=24&type=section&id=%E6%B5%81%E5%8A%A8%E8%B5%84%E9%87%91%E4%B8%8E%E8%B4%A2%E5%8A%A1%E8%B5%84%E6%BA%90) [Overview of Liquidity and Financial Resources](index=24&type=section&id=%E6%B5%81%E5%8B%95%E8%B3%87%E9%87%91%E5%8F%8A%E8%B2%A1%E5%8B%99%E8%B3%87%E6%BA%90%E6%A6%82%E6%B3%81) This chapter outlines the company's cash flow, showing net cash used in operating activities of **RMB 44.1 million**, primarily impacted by R&D, administrative, and selling expenses, with shareholder contributions and equity financing as main liquidity sources Cash Flow Summary | Cash Flow Category | For the Six Months Ended 2025 June 30 (RMB million) | | :--- | :--- | | Net Cash Used in Operating Activities | (44.1) | | Net Cash From Investing Activities | 0.8 | | Net Cash From Financing Activities | 42.1 | - As of June 30, 2025, cash and cash equivalents amounted to **RMB 53.2 million**, a decrease of **RMB 1.4 million** compared to December 31, 2024[56](index=56&type=chunk) [Gearing Ratio](index=25&type=section&id=%E8%B3%87%E7%94%A2%E8%B2%A0%E5%82%B5%E6%AF%94%E7%8E%87) This chapter states that as of June 30, 2025, the Group's gearing ratio was **0%** because interest-bearing borrowings were less than cash and cash equivalents - As of June 30, 2025, the Group's gearing ratio was **0%**, as interest-bearing borrowings were less than cash and cash equivalents[57](index=57&type=chunk) [Indebtedness](index=25&type=section&id=%E5%82%B5%E5%8B%99) This chapter discloses the company's outstanding borrowing balance and unutilized bank facilities, noting a decrease in lease liabilities Indebtedness Summary | Indicator | 2025 June 30 (RMB million) | | :--- | :--- | | Outstanding Borrowing Balance | 31.6 | | Unutilized Bank Facilities | 75.6 | | Lease Liabilities | 2.2 | - Lease liabilities decreased from **RMB 3.0 million** as of December 31, 2024, to **RMB 2.2 million** as of June 30, 2025, primarily due to lease payments[58](index=58&type=chunk) [Capital Commitments](index=25&type=section&id=%E8%B5%84%E6%9C%AC%E6%89%BF%E6%93%94) This chapter discloses that as of June 30, 2025, the company had contracted but unprovided capital commitments of **RMB 301.3 million**, primarily related to construction and services for its industrial park - As of June 30, 2025, the company had contracted but unprovided capital commitments of **RMB 301.3 million**, related to the purchase of construction and services for the Group's industrial park[59](index=59&type=chunk) [Pledge of Assets and Contingent Liabilities](index=25&type=section&id=%E8%B5%84%E7%94%A2%E6%8A%B5%E6%8A%BC%E4%B8%8E%E6%88%96%E7%84%B6%E8%B2%A0%E5%82%B5) This chapter confirms that as of June 30, 2025, the Group had no pledge of assets or any significant contingent liabilities - As of June 30, 2025, the Group had no pledge of assets[60](index=60&type=chunk) - As of June 30, 2025, the Group had no significant contingent liabilities[61](index=61&type=chunk) [Material Investments, Material Acquisitions and Disposals](index=25&type=section&id=%E9%87%8D%E5%A4%A7%E6%8A%95%E8%B5%84%E3%80%81%E9%87%8D%E5%A4%A7%E6%94%B6%E8%B3%BC%E5%8F%8A%E5%87%BA%E5%94%AE%E4%BA%8B%E9%A0%85) This chapter states that during the reporting period, the company held no material investments and did not undertake any material acquisitions or disposals of subsidiaries, associates, or joint ventures - During the reporting period, the company held no material investments and did not undertake any material acquisitions or disposals of subsidiaries, associates, or joint ventures[62](index=62&type=chunk) [Foreign Exchange Risk](index=25&type=section&id=%E5%A4%96%E5%8C%AF%E9%A2%A8%E9%99%A9) This chapter explains that the company faces foreign currency risk primarily from USD-denominated bank cash, currently without a hedging policy, but management monitors and considers future hedging measures - The company faces foreign currency risk primarily arising from bank cash denominated in US dollars[63](index=63&type=chunk) - The company currently has no foreign currency hedging policy, but management monitors foreign exchange risk and considers future hedging measures[63](index=63&type=chunk) [Future Plans for Material Investments or Capital Assets](index=25&type=section&id=%E9%87%8D%E5%A4%A7%E6%8A%95%E8%B3%87%E6%88%96%E8%B3%87%E6%9C%AC%E8%B3%87%E7%94%A2%E4%B9%8B%E6%9C%AA%E4%BE%86%E8%A8%88%E5%8A%83) This chapter outlines the company's future development strategy, including expanding Chinese and global markets, driving product development, growing through organic means and M&A, and planning to support capital expenditures via internal funds and bank loans - The Group will continue to expand its markets in China and globally, drive product development, and grow through organic development, mergers, and acquisitions[64](index=64&type=chunk) - The company will utilize various financing channels to support capital expenditures, including internal funds and bank loans, with sufficient bank credit facilities currently available[64](index=64&type=chunk) [Employees](index=26&type=section&id=%E5%83%B1%E5%93%A1) This chapter details the company's employee situation as of June 30, 2025, with **214** full-time employees and total employee benefit expenses of approximately **RMB 26.6 million**, highlighting its focus on employee training, development, and a pre-IPO share option scheme to attract and incentivize talent - As of June 30, 2025, the Group employed **214** full-time employees, with total employee benefit expenses of approximately **RMB 26.6 million**[65](index=65&type=chunk) - The company provides continuous education and training programs for management and other employees, assessing salaries, promotion opportunities, and career development based on performance[65](index=65&type=chunk) - The company approved the adoption of a pre-IPO share option scheme on December 10, 2021, aimed at attracting, incentivizing, and retaining talent[65](index=65&type=chunk) [Financial Resources and Use of Proceeds](index=26&type=section&id=%E8%B4%A2%E5%8A%A1%E8%B5%84%E6%BA%90%E4%B8%8E%E8%B5%84%E9%87%91%E7%94%A8%E9%80%94) [2025 Subscription](index=26&type=section&id=2025%E5%B9%B4%E8%AA%8D%E8%B3%BC%E4%BA%8B%E9%A0%85) This chapter discloses that on May 26, 2025, the company entered into a subscription agreement with Apsara Technology Limited, completing the allotment and issuance of **233,559,800** shares, generating net proceeds of **HKD 37.47 million** - On May 26, 2025, the company entered into a subscription agreement with Apsara Technology Limited for the allotment and issuance of **233,559,800** shares at a subscription price of **HKD 0.163** per share[66](index=66&type=chunk) - The subscription was completed on June 20, 2025, with total net proceeds of **HKD 37.47 million** received[66](index=66&type=chunk) [Use of Proceeds from Listing](index=27&type=section&id=%E4%B8%8A%E5%B8%82%E6%89%80%E5%BE%97%E6%AC%BE%E9%A0%85%E7%94%A8%E9%80%94) This chapter states that the company was listed on July 8, 2022, with net proceeds from the global offering of approximately **HKD 78.6 million**, all of which were fully utilized as described in the prospectus by December 31, 2024 - Net proceeds from the global offering of approximately **HKD 78.6 million** were fully utilized by December 31, 2024[67](index=67&type=chunk) [Use of Proceeds from 2025 Subscription](index=27&type=section&id=2025%E5%B9%B4%E8%AA%8D%E8%B3%BC%E4%BA%8B%E9%A0%85%E4%B9%8B%E6%89%80%E5%BE%97%E6%AC%BE%E9%A0%85%E7%94%A8%E9%80%94) This chapter details the planned use of net proceeds from the 2025 subscription, primarily allocated to R&D for existing and new products, business development and marketing, and general working capital Planned Use of 2025 Subscription Proceeds | Planned Use | Percentage of Net Proceeds (%) | Unutilized Proceeds (HKD million) | Expected Timeline | | :--- | :--- | :--- | :--- | | R&D for Existing and New Products and Candidate Products | 20.00 | 7.49 | October 31, 2025 | | Business Development and Marketing for Existing and New Products and Candidate Products | 60.00 | 22.48 | December 31, 2025 | | General Working Capital for the Group | 20.00 | 7.49 | August 31, 2025 | | **Total** | **100.00** | **37.46** | | - As of June 30, 2025, the net proceeds from the 2025 subscription remained unutilized[68](index=68&type=chunk) [Interim Dividend](index=27&type=section&id=%E4%B8%AD%E6%9C%9F%E8%82%A1%E6%81%AF) This chapter confirms that the Board does not recommend the payment of any interim dividend for the six-month period ended June 30, 2025 - The Board does not recommend the payment of any interim dividend for the six-month period ended June 30, 2025[69](index=69&type=chunk) [Events After the Reporting Period](index=28&type=section&id=%E5%A0%B1%E5%91%8A%E6%9C%9F%E9%96%93%E5%BE%8C%E4%BA%8B%E9%A0%85) This chapter notes that, apart from disclosed changes in Board members, the Group has not undertaken any other significant post-reporting period events from June 30, 2025, to the date of this announcement - Except for changes in Board members, the Group has not undertaken any other significant post-reporting period events from June 30, 2025, to the date of this announcement[71](index=71&type=chunk) [Corporate Governance](index=28&type=section&id=%E4%BC%81%E6%A5%AD%E7%AE%A1%E6%B2%BB) [Corporate Governance Practices](index=28&type=section&id=%E4%BC%81%E6%A5%AD%E7%AE%A1%E6%B2%BB%E5%B8%B8%E8%A6%8F) This chapter explains the company's commitment to maintaining high standards of corporate governance, having adopted the Corporate Governance Code set out in Appendix C1 of the Listing Rules - The Group is committed to maintaining high standards of corporate governance and has adopted the Corporate Governance Code set out in Appendix C1 of the Listing Rules[72](index=72&type=chunk) [Changes in Board Members](index=28&type=section&id=%E8%91%A3%E4%BA%8B%E6%9C%83%E6%88%90%E5%93%A1%E8%AE%8A%E5%8B%95) This chapter lists Board member changes effective July 15, 2025, including resignations and appointments of the CEO, executive directors, and members of the Remuneration and Nomination Committees - Mr. Huo Yunfei resigned as Chief Executive Officer but remains Chairman of the Board, Executive Director, and Authorised Representative[73](index=73&type=chunk) - Mr. Lü Yonghui resigned as Executive Director but remains Co-Chief Executive Officer[73](index=73&type=chunk) - Mr. Zhu Zeke was appointed Executive Director and Co-Chief Executive Officer, Ms. Duan Jing was appointed Executive Director and a member of the Remuneration and Nomination Committees, and Mr. Zhao Hui was appointed Independent Non-executive Director, Chairman of the Nomination Committee, and a member of the Audit Committee[73](index=73&type=chunk) [Deviation from and Compliance with Corporate Governance Code](index=29&type=section&id=%E4%BC%81%E6%A5%AD%E7%AE%A1%E6%B2%BB%E5%AE%88%E5%88%99%E5%81%8F%E7%A6%BB%E5%8F%8A%E9%81%B5%E5%AE%88%E6%83%85%E5%86%B5) This chapter explains that the company deviated from the Corporate Governance Code's requirement for separation of Chairman and CEO roles during the reporting period, but has fully complied since Mr. Huo Yunfei's resignation as CEO - During the reporting period, Mr. Huo Yunfei concurrently held the roles of Chairman of the Board and Chief Executive Officer, constituting a deviation from Code Provision C.2.1 of the Corporate Governance Code[74](index=74&type=chunk) - Since Mr. Huo Yunfei ceased to be Chief Executive Officer on July 15, 2025, the company has fully complied with Code Provision C.2.1 of Part 2 of the Corporate Governance Code set out in Appendix C1 to the Listing Rules[74](index=74&type=chunk) [Non-compliance with Listing Rules and Remedial Actions](index=29&type=section&id=%E6%9C%AA%E8%83%BD%E9%81%B5%E5%AE%88%E4%B8%8A%E5%B8%82%E8%A6%8F%E5%89%87%E6%A2%9D%E6%96%87%E5%8F%8A%E8%A3%9C%E6%95%91%E6%8E%AA%E6%96%BD) This chapter notes that the company previously failed to comply with Listing Rules regarding Board composition and committee membership due to an independent non-executive director's resignation, but has since regained compliance through the appointment of a new independent non-executive director and committee adjustments - Following Mr. Li Haomin's resignation as an independent non-executive director, the company failed to comply with Listing Rules 3.10(1), 3.10A, 3.21, 3.25, and 3.27A[76](index=76&type=chunk) - Following the appointment of Mr. Zhao Hui as an independent non-executive director and changes in the composition of Board committees effective July 15, 2025, the company has regained compliance with the relevant Listing Rules[76](index=76&type=chunk) [Model Code for Securities Transactions](index=30&type=section&id=%E9%80%B2%E8%A1%8C%E8%AD%89%E5%88%B8%E4%BA%A4%E6%98%93%E7%9A%84%E6%A8%99%E6%BA%96%E5%AE%88%E5%89%87) This chapter confirms that the company has adopted the Model Code set out in Appendix C3 of the Listing Rules, and all directors complied with it during the reporting period - The company has adopted the Model Code set out in Appendix C3 of the Listing Rules, and all directors complied with it for the six months ended June 30, 2025[77](index=77&type=chunk) [Purchase, Sale or Redemption of the Company's Listed Securities](index=30&type=section&id=%E8%B3%BC%E8%B2%B7%E3%80%81%E5%87%BA%E5%94%AE%E6%88%96%E8%B4%96%E5%9B%9E%E6%9C%AC%E5%85%AC%E5%8F%B8%E4%B9%8B%E4%B8%8A%E5%B8%82%E8%AD%89%E5%88%B8) This chapter confirms that for the six months ended June 30, 2025, neither the company nor any of its subsidiaries purchased, sold, or redeemed any of the company's listed securities - For the six months ended June 30, 2025, neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed securities[78](index=78&type=chunk) [Audit Committee](index=30&type=section&id=%E5%AF%A9%E6%A0%B8%E5%A7%94%E5%91%98%E6%9C%83) This chapter describes the Audit Committee's composition and responsibilities, confirming its review of the Group's unaudited condensed interim financial information for the six months ended June 30, 2025 - The Audit Committee comprises three independent non-executive directors: Mr. Liao Chuanjiang (Chairman), Mr. Chen Xuefeng, and Mr. Zhao Hui[79](index=79&type=chunk) - The Audit Committee's primary responsibilities include assisting the Board in providing independent opinions on financial reporting procedures, internal control, and risk management systems, and overseeing the audit process[79](index=79&type=chunk) - The Audit Committee has reviewed the Group's unaudited condensed interim financial information for the six months ended June 30, 2025[79](index=79&type=chunk) [Publication of Interim Results Announcement and Interim Report](index=30&type=section&id=%E5%88%8A%E7%99%BC%E4%B8%AD%E6%9C%9F%E6%A5%AD%E7%B8%BE%E5%85%AC%E5%91%8A%E5%8F%8A%E4%B8%AD%E6%9C%9F%E5%A0%B1%E5%91%8A) This chapter states that the interim results announcement has been published on the Stock Exchange and company websites, and the 2025 interim report, containing all required information, will be dispatched to shareholders and posted on relevant websites in due course - This interim results announcement is published on the Stock Exchange website (www.hkexnews.hk) and the Company's website (www.rainmed.com)[80](index=80&type=chunk) - The 2025 interim report, containing all information required by the Listing Rules, will be dispatched to shareholders and posted on the respective websites of the Stock Exchange and the Company in due course[80](index=80&type=chunk) [Appendix](index=31&type=section&id=%E9%99%84%E9%8C%84) [Definitions](index=31&type=section&id=%E9%87%8B%E7%BE%A9) This chapter provides definitions for key terms and abbreviations used in this interim results announcement to ensure clear understanding of the report content - This chapter provides definitions for key terms such as 'Company', 'CAD', 'caFFR', 'caIMR', 'CE Mark', 'FFR', 'IMR', 'IVD', 'KOL', 'Listing Rules', 'NMPA', 'PCI', 'RMB', 'Shares', 'STEMI', and 'Stock Exchange'[81](index=81&type=chunk)[82](index=82&type=chunk)[83](index=83&type=chunk)[86](index=86&type=chunk) [Board Approval and Composition](index=34&type=section&id=%E8%91%A3%E4%BA%8B%E6%9C%83%E6%89%B9%E5%87%86%E5%8F%8A%E7%B5%84%E6%88%90) This chapter confirms the Board's approval of this announcement on August 28, 2025, and lists the Board's composition as of the announcement date - This announcement was approved by the Board on August 28, 2025[85](index=85&type=chunk) - As of the announcement date, the Board comprises three executive directors, three non-executive directors, and three independent non-executive directors[85](index=85&type=chunk)

本文源自：金融界 作者：行情君 8月20日，润迈德-B(02297)盘中下跌10.0%，截至14:25，报0.45元/股，成交1757.63万元。 润迈德医疗有限公司是一家致力于成为全球领先的血管介入手术机器人的高新技术企业，主导产品包括 caFFR系统、caIMR系统及FlashBot血管介入手术机器人。公司已构建全球化的研发、生产、销售、服 务网络，与多家顶级医学中心合作，制定严格的质检体系，成功获得医疗器械质量管理体系认证。 截至2024年年报，润迈德-B营业总收入3982.4万元、净利润-1.13亿元。 ...

截至2024年年报，润迈德-B营业总收入3982.4万元、净利润-1.13亿元。 本文源自：金融界 作者：行情君 8月19日，润迈德-B(02297)盘中上涨32.43%，截至15:59，报0.49元/股，成交1892.34万元。 润迈德医疗有限公司是一家致力于成为全球领先的血管介入手术机器人的高新技术企业，主导产品包括 caFFR系统、caIMR系统及FlashBot血管介入手术机器人。公司已构建全球化的研发、生产、销售、服 务网络，与多家顶级医学中心合作，制定严格的质检体系，成功获得医疗器械质量管理体系认证。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示，概不就因本公告的全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Rainmed Medical Limited 潤邁德醫療有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2297） 董事會會議召開日期 潤邁德醫療有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於二零二五年八 月二十八日（星期四）舉行董事會會議，藉以(其中包括)考慮並批准本公司及其附屬公司截 至二零二五年六月三十日止六個月之未經審計的中期業績及其刊發，並考慮派發中期股息 (如有)，以及處理其他事項。 承董事會命 潤邁德醫療有限公司 董事會主席兼執行董事 霍雲飛 香港，二零二五年八月十八日 於本公告日期，董事會由執行董事霍雲飛先生、朱則柯先生及段靜女士；非執行董事霍雲龍博士、王霖先生及衡磊先 生；及獨立非執行董事廖船江先生丶陳雪峰先生及趙暉先生組成。 ...